Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05744440 | Safety and Efficacy of Allogenic NK Cells in Combination With Chemotherapy in the Treatment of r/r AML After Allo-HSCT | unknown | Early Phase 1 | 12 | Xuzhou Medical UniversityOTHER | 1 | Feb 27, 2023 | clinicaltrials |
| NCT03467256 | CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL | unknown | Phase 1 / Phase 2 | 18 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Feb 24, 2023 |
| clinicaltrials |
| NCT05744037 | Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells | unknown | Phase 2 | 30 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT05728632 | Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines(CONTROL) | unknown | Phase 3 | 80 | Giulio StefaniniOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT05739188 | Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM | unknown | Phase 1 / Phase 2 | 18 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT05740891 | AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma | unknown | Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT05740917 | To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS | unknown | Phase 1 | 82 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 23, 2023 | clinicaltrials |
| NCT05739227 | Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies | unknown | Early Phase 1 | 12 | Xuzhou Medical UniversityOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT05739630 | M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia | unknown | Phase 2 / Phase 3 | 60 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT04688021 | A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT. | unknown | Phase 2 | 46 | Yi LuoOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04809181 | Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients | unknown | Phase 2 | 95 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05712083 | A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma | unknown | Phase 2 | 40 | Zhejiang UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT03573362 | Effect of Needle Size in Diagnostic Yield of EBUS-TBNA in Sarcoidosis and Lymphoma | unknown | N/A | 50 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT04669067 | TL-895 and KRT-232 Study in Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 18 | Telios Pharma, Inc.INDUSTRY | 8 | Feb 17, 2023 | clinicaltrials |
| NCT04309084 | Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | unknown | Phase 1 | 29 | Celularity IncorporatedINDUSTRY | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02172872 | "InDACtion" vs "3+7" Induction in AML | unknown | Phase 3 | 606 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Feb 15, 2023 | clinicaltrials |
| NCT05634915 | Clinical Study of rATG Individualized Administration in Haploidentical Hematopoietic Stem Cell Transplantation | unknown | Phase 4 | 90 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT05400876 | To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma | unknown | Phase 1 / Phase 2 | 92 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05727683 | CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 33 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05381662 | CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment | unknown | Phase 1 / Phase 2 | 10 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Feb 10, 2023 | clinicaltrials |
| NCT02338479 | Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies | unknown | — | 340 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Feb 8, 2023 | clinicaltrials |
| NCT03797170 | Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma | unknown | — | 50 | University of BolognaOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT04092348 | FoxO3a and PU.1 in Acute Lymphoblastic Leukemia | unknown | — | 53 | Assiut UniversityOTHER | 0 | Feb 8, 2023 | clinicaltrials |
| NCT05717634 | Endometrial Changes in Breast Cancer Women. | unknown | — | 829 | Regina Elena Cancer InstituteOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05718401 | The Diagnostic Pattern and Prognosis of Multiple Myeloma Patients With Myocardial Amyloidosis Were Evaluated by NMR Based Metabolomics | unknown | — | 500 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT02047578 | Targeted Busulfan, Fludarabine, Etoposide Conditioning Regimen for HSCT in Childhood and Adolescent ALL. | unknown | Phase 2 | 38 | Seoul National University HospitalOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT04381741 | CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma(CICPD) | unknown | Phase 1 | 24 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT04706936 | Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma | unknown | Phase 1 | 25 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT04887025 | Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma | unknown | Phase 1 | 25 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05210907 | Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia | unknown | Phase 1 | 5 | Seoul National University HospitalOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05585996 | Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma | unknown | Phase 1 | 70 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05667155 | Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma | unknown | Phase 1 | 48 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05498259 | Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL | unknown | Phase 2 | 46 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Feb 3, 2023 | clinicaltrials |
| NCT05526638 | Serum and Tissue Level of Interleukin-15 (IL-15) and IL-15 Receptor Alpha (IL-15Rα) in Mycosis Fungoides | unknown | N/A | 15 | Cairo UniversityOTHER | 1 | Feb 2, 2023 | clinicaltrials |
| NCT05432414 | PVd Versus Vd in NDMM Patients With RI | unknown | Phase 2 | 79 | RenJi HospitalOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05381181 | Safety and Efficacy Evaluation of Next-generation CD19-UCART | unknown | Phase 1 | 20 | Bioray LaboratoriesINDUSTRY | 0 | Jan 27, 2023 | clinicaltrials |
| NCT04280133 | CAR T-CELL Therapy Educational Video Trial | unknown | N/A | 80 | Massachusetts General HospitalOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05698303 | A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 | 12 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 26, 2023 | clinicaltrials |
| NCT03252600 | Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis | unknown | Phase 2 | 53 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT05693519 | GastroIntestinal Cancer in Children and Adolescents(GICCA) | unknown | — | 2,500 | Paul G. Kemps, MDOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT05693012 | Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma | unknown | — | 398 | Qiu LuguiOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT05017337 | Breast-implant ASsocIated anaplastIc Large Cell Lymphoma and CApsular Contracture(BASILICA) | unknown | — | 100 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT05690191 | Chidamide in Patients With Recurrent and Refractory Diffuse Large b | unknown | — | 169 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT05691153 | ThisCART19A for B-NHL Relapsed After Auto-CAR T | unknown | Phase 1 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT05505864 | Assessing Sedentary Behaviour in Adults With Type 2 Diabetes - A Randomized Controlled Trial | unknown | N/A | 52 | Western UniversityOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT05007418 | Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 | 54 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05679687 | ThisCART19A Bridging to alloHSCT for R/R B-ALL | unknown | Phase 1 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 11, 2023 | clinicaltrials |
| NCT05680038 | Penpulimab in Maintenance Therapy in Lymphoma | unknown | — | 167 | WEI XUOTHER | 0 | Jan 11, 2023 | clinicaltrials |
| NCT04287855 | Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma | unknown | Phase 2 | 82 | Poitiers University HospitalOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT05672420 | Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies | unknown | Phase 1 / Phase 2 | 181 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 5, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Feb 27, 2023source: clinicaltrials